Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Krystal Biotech

NASDAQ KRYS
$164.10 0.0000 0.0000%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 21 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

4.81B
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
4.45B
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.15
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
29.29M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
32.27 %

Upcoming events Krystal Biotech

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Krystal Biotech

Stock analysis Krystal Biotech

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
84.09 28.84
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.
6.17 4.35
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-71.08 10.00
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
5.70 0.65
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
7.15 7.67

Price change Krystal Biotech per year

40.04$ 87.29$
Min Max

Summary analysis Krystal Biotech

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Krystal Biotech

Revenue and net income Krystal Biotech

All parameters

Stock news Krystal Biotech

All news
7 August 2023 в 17:45

Krystal Biotech Shares Tumble 10% on Wider 2Q Loss

7 August 2023 в 17:45

Krystal Biotech Shares Tumble 10% on Wider 2Q Loss

22 May 2023 в 17:25

Krystal Biotech Shares Rise 13% After $160M Private Placement Equity

22 May 2023 в 17:25

Krystal Biotech Shares Rise 13% After $160M Private Placement Equity

19 May 2023 в 21:45

Krystal Biotech stock rises after FDA approves treatment for rare skin disease

18 April 2023 в 14:00

Krystal Biotech started at buy with $102 stock price target at Stifel Nicolaus

9 January 2023 в 17:05

Krystal Biotech’s stock is down on delayed PDUFA date

29 November 2021 в 22:26

Krystal Biotech Shares More Than Double After Dystrophic EB Trial Meets Objectives

29 November 2021 в 22:20

Krystal Biotech Shares More Than Double After Dystrophic EB Trial Meets Objectives

29 November 2021 в 15:50

Krystal Biotech Shares More Than Double After Dystrophic EB Trial Meets Objectives

29 November 2021 в 15:45

Krystal Biotech Shares More Than Double After Dystrophic EB Trial Meets Objectives

About company Krystal Biotech

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and acne scars; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx for other rare lung disease. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Address:
2100 Wharton Street, Pittsburgh, PA, United States, 15203
Company name: Krystal Biotech
Issuer ticker: KRYS
ISIN: US5011471027
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2017-09-20
Sector: Healthcare
Industry: Biotechnology
Site: https://www.krystalbio.com

On which stock exchange are Krystal Biotech (KRYS) stocks traded?

Krystal Biotech (KRYS) stocks are traded on NASDAQ.

What is the ticker of Krystal Biotech stocks (KRYS)?

The stock ticker of Krystal Biotech’s stocks or in other words, the code is KRYS. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Krystal Biotech (KRYS) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Krystal Biotech (KRYS) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Krystal Biotech (KRYS) stocks traded?

Krystal Biotech (KRYS) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Krystal Biotech (KRYS) stocks today?

The current price of Krystal Biotech stocks on 19.05.2024 is 164.1 dollars. per share.

What is the dynamics of Krystal Biotech (KRYS) stocks from the beginning of the year?

Krystal Biotech (KRYS) quotes have increased by 31.32% from the beginning of the year up to 164.1 dollars. per 1 stocks.

How much did Krystal Biotech (KRYS) stocks increase in мае 2024?

This month Krystal Biotech (KRYS) quotes have increased by 2.77% to 164.1 dollars. per share.

How much are Krystal Biotech (KRYS) stocks worth?

Today, on October, 19.05.2024 Krystal Biotech’s (KRYS) stocks cost 164.1 dollars..

What is the market capitalization of Krystal Biotech (KRYS)?

Capitalization is the market value of Krystal Biotech (KRYS) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 19.05.2024, the market capitalization of Krystal Biotech (KRYS) is estimated at about 4806653100 dollars.